Sugi Predict

Sugi Predict / Targets / DSTYK

DSTYK

Dual serine/threonine and tyrosine protein kinase · Q6XUX3 · DSTYK on Sugi Atlas →

2,263 patent compounds predicted against DSTYK, 1,632 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Dabrafenib Dabrafenib (SCHEMBL806377) 1.00 1/20
Rg-547 Rg-547 (SCHEMBL2397067) 1.00 1/20
Dabrafenib Dabrafenib (SCHEMBL1127269) 0.95 1/20
SCHEMBL3522526 SCHEMBL3522526 0.91 1/20
SCHEMBL2193062 SCHEMBL2193062 0.90 1/20
SCHEMBL3522463 SCHEMBL3522463 0.89 1/20
SCHEMBL4350447 SCHEMBL4350447 0.87 1/20
SCHEMBL4354399 SCHEMBL4354399 0.86 1/20
SCHEMBL4355436 SCHEMBL4355436 0.86 1/20
SCHEMBL2191986 SCHEMBL2191986 0.85 1/20
SCHEMBL3521770 SCHEMBL3521770 0.84 1/20
SCHEMBL2194314 SCHEMBL2194314 0.84 1/20
SCHEMBL4348141 SCHEMBL4348141 0.84 1/20
SCHEMBL1127301 SCHEMBL1127301 0.83 1/20
SCHEMBL1127613 SCHEMBL1127613 0.83 1/20
SCHEMBL1127717 SCHEMBL1127717 0.83 1/20
SCHEMBL4352814 SCHEMBL4352814 0.82 1/20
SCHEMBL4355426 SCHEMBL4355426 0.81 1/20
SCHEMBL1128208 SCHEMBL1128208 0.81 1/20
SCHEMBL2193568 SCHEMBL2193568 0.81 1/20

Clinical trials — most relevant to DSTYK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL PHASE2COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) PHASE2ACTIVE_NOT_RECRUITING
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation PHASE2COMPLETED
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP PHASE1/PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency PHASE1RECRUITING
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib EARLY_PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Tumor Kinase Inhibitor Concentrations Measured by PET nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia nanUNKNOWN
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2) nanCOMPLETED
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC nanUNKNOWN
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a DSTYK binder may also engage these)

ProteinNameSimilarity
Q4VSN4 — 1.000 Q4VSN4 →
Q6XUX1 — 1.000 Q6XUX1 →
Q4TVR5 — 1.000 Q4TVR5 →
Q4VSN5 — 1.000 Q4VSN5 →
A2CI34 — 1.000 A2CI34 →
Q6XUX0 — 1.000 Q6XUX0 →
Q20CR4 — 1.000 Q20CR4 →
Q4VSN3 — 1.000 Q4VSN3 →
Q6XUX2 — 1.000 Q6XUX2 →
Q4VSN2 — 0.998 Q4VSN2 →
Q4VSN1 — 0.997 Q4VSN1 →
Q67E01 — 0.994 Q67E01 →
Q95KV0 — 0.994 Q95KV0 →
O18412 — 0.994 O18412 →
A2CI35 — 0.993 A2CI35 →
Q8R4Z9 — 0.993 Q8R4Z9 →
CHUK Inhibitor of nuclear factor kappa-B kinase subunit alpha 0.993 landscape →
Q811U4 — 0.992 Q811U4 →
Q6GM53 — 0.992 Q6GM53 →
Q67E00 — 0.992 Q67E00 →
O15050 — 0.992 O15050 →
Q9UHY1 — 0.991 Q9UHY1 →
Q9NSY0 — 0.991 Q9NSY0 →
Q9D5Z5 — 0.991 Q9D5Z5 →
Q5SSH7 — 0.991 Q5SSH7 →
Q4R8X0 — 0.991 Q4R8X0 →
Q99J45 — 0.991 Q99J45 →
Q9Z2R9 — 0.991 Q9Z2R9 →
Q6NU22 — 0.991 Q6NU22 →
Q95KV1 — 0.990 Q95KV1 →